Most comprehensive ADC conference dedicated to Asia-Pacific—where decision-makers gather to exchange ideas, celebrate excellence, explore opportunities, and drive business deals

John Flygare is currently Head of the ADC and Large Molecule Innovation Group at Eli Lilly. John has over 25 years of experience in the biotech and pharmaceutical industry. Most recently, John was Chief Scientific Offiicer of Firefly Biologics, a company he co-founded to focus on Degrader-Antibody Conjugates. Prior to FFB, John held leadership roles at Merck and Genentech. John has also lectured extensively at Stanford University where he has taught >30 undergraduate and graduate courses in organic and medicinal chemistry. John has authored or co-authored >100 publications and is an inventor on >50 issued US Patents

Ben is the Vice President of Antibody-Drug Conjugates at Hummingbird Bioscience. With more than 16 years’ experience in the biopharma sector, Ben leads the strategy and development of the Antibody-Drug Conjugates platform and programs at Hummingbird Bioscience. Ben also held strategy and preclinical roles since joining Hummingbird Bioscience in 2020.

Prior to joining Hummingbird Bioscience, Ben advised companies on commercial strategy in APAC at ZS Associates, a healthcare-focused management consulting firm. Ben has accumulated a decade of experience in medicinal chemistry research in a wide range of therapeutic areas including oncology, tropical disease, diabetes, cystic fibrosis, and lysosomal storage diseases at Novartis, the Institute of Cancer Research, and the University of Oxford.

Ben holds a M.Chem. in Chemistry and a D.Phil in Organic Chemistry from the University of Oxford.

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into clinic stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.

David Teng-Yi Huang, Ph.D., is Senior Director of ADC Enabling Technologies at OBI Pharma. With expertise in carbohydrate chemistry and glycoengineering, he leads the development of OBI’s proprietary ADC platforms, including GlycOBI®, ThiOBI®, EndoSymeOBI®, and HYPrOBI™. His research focuses on site-specific conjugation, homogeneous ADCs, and novel linker-payload strategies to enhance stability, therapeutic index, and manufacturability. Dr. Huang has advanced multiple clinical and preclinical ADC programs, including dual-payload and bispecific formats, while contributing to OBI’s intellectual property portfolio and business development partnerships. He earned his Ph.D. in Chemistry from National Tsing Hua University and trained at Academia Sinica in glycoscience.

Dr. Moore joined Zymeworks in July 2022 serving as Chief Scientific Officer and heading early stage RnD efforts focused on the development of next generation ADCs and multispecifics, with multiple new therapeutics entered or on track to enter clinical development. Paul has over 25 years of US-based experience in biologics drug discovery and development in biotechnology research, with his career efforts leading to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients. Before joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. He began his biotech career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received a PhD in molecular genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 80 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

An experienced and versatile Ph.D. pharmaceutical R&D/Scientific Affairs professional with about 15 years of experience including 8 years as Founder and CEO of Pinotbio, Inc. Experience in drug discovery programs in the areas of oncology – 2 INDs and many on-going pre-clinical programs. Formerly patent examiner in Korea Intellectual Property Office (KIPO) and possesses extensive knowledge about patents and related matters. Has led many scientific evaluations and due diligence of licensing/partnership opportunities in the academic institute and industry in the field of oncology. Extensive knowledge and understanding of drug discovery and preclinical development, especially related to Antibody-Drug Conjugate (ADC) platforms and ADC candidates. Deep understanding of medicinal and process chemistry, especially related with camptothecin payloads and ADC linkers.

Currently, CEO of Pinotbio, Inc. – a South-Korea based biotech company focusing on the discovery and development of novel ADC platforms.

Dr Veronica Diermayr is a molecular biologist with more than 25 years of experience in Translational sciences.

Born and educated in Vienna, Austria, Veronica came to Singapore 25 years ago. She has worked in drug development in the area of immunology and infectious diseases, but her main focus has been in oncology, doing preclinical and clinical development for novel small molecules, biologics and antibody-drug conjugates.

Having worked for an MNC (Novartis), a biotech (S*BIO) where she significantly contributed to the early preclinical and clinical development of the now marketed drug Vonjo (pacritinib), and Singapore-government-funded drug development centres (D3, EDDC), she has deep technical expertise across a wide range of translational work, spanning from animal pharmacology, biomarker research, clinical operations, to CMC. She has been leading multiple therapeutics from discovery through Phase 2 trials. In the past 10 years she has led 3 successful US INDs and 4 Clinical Trial Authorisations in Singapore, that included healthy volunteer studies as well as early phase clinical studies for oncology. Veronica has been leading the EDDC flagship program for the ADC EBC-129 as an Asset Lead for the past 5 years from lead stage into Ph 2 clinical trials with a diagnostic IHC assay developed simultaneously. She’s also leading the Translational Science group overseeing in vivo studies and biomarker development for a novel payload and several novel ADCs and TcEs, including bispecific, bi-paratropic and dual payload ADCs.

Dr. Changshou Gao is currently CTO and Head of Biologics Research at Shanghai Allist Pharmaceuticals. From 2020–2024, he served as CTO, SVP, and US Site Head at Innovent Biologics, advancing five ADCs and multiple projects into early clinical development. Prior to that, he spent over 18 years at MedImmune/AstraZeneca, leading biologics discovery, bispecific antibodies, ADCs, nnAA platforms, targeted nanoparticles, and AAV gene therapy. His teams advanced more than 20 therapeutic antibodies into clinical trials across oncology, immunology, infectious disease, and metabolic disorders. Dr. Gao earned his Ph.D. in Chemistry and Molecular Biology from The Scripps Research Institute.

Dr. Ee Xien Ng is a Technical Expert and has been with BioReliance® Contract Testing Services, Merck Life Science since 2020. Ee Xien is responsible for supporting technical discussion within internal BioReliance® team and external biopharmaceutical clients on biologics QC testing requirement and consideration. Ee Xien focuses on the discussion around adoption of new testing technologies such as NGS and nucleic acid-based techniques to advance and accelerate biosafety QC testing. Within Merck, Ee Xien had also acted as a GLP Study Director for close to 40 Viral Clearance IND/BLA studies for biopharmaceutical companies across the APAC region and has the relevant knowledge on downstream processing and virology. Before joining Merck, he has experience working on cell manufacturing and micro-bioreactor projects for cell-based therapy with start-up company and researchers from the US and Singapore. Dr. Ng obtained his Ph.D. in Biomedical Engineering from the National University of Singapore and conducted his postdoctoral research on critical analytics for manufacturing personalized medicine at Singapore-MIT Alliance for Research and Technology.

Dr. Jun Hu is currently Head of Client Enabling Center of Excellence and Singapore Site Management at WuXi XDC, by leading a diversified team of talents, including PMs and BDs to help enable global partners’ success on various bioconjugate programs. He is currently leading a team to support construct and manage new manufacturing site at Tuas Singapore. He has nearly 15 years’ comprehensive experience in process development, GMP manufacturing, CMC management, business development, operational excellence as well as team management. Dr. Hu obtained his Ph.D. degree in Bioengineering from Tokyo Institute of Technology, and bachelor’s degree in chemical engineering from Tsinghua University. Before he joined WuXi Biologics/WuXi XDC he was working in Takeda Pharmaceutical Company Japan on process development and clinical GMP manufacturing.

Dr. Pini Tsukerman is an immunologist and co-founder of Nectin Therapeutics, a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) and immune-oncology therapies. He established Nectin’s R&D organization, built its IP portfolio, and led the company’s scientific and development strategy from inception through clinical proof-of-concept. Under his leadership, Nectin has advanced multiple ADC programs to IND-enabling stages, integrating novel payload and linker technologies, and forged strategic collaborations with leading global biopharmaceutical companies to accelerate development. Dr. Tsukerman also guided the company’s lead program, NTX1088, from concept to clinical validation, advancing Nectin’s mission to deliver transformative therapies for resistant cancers.

Giorgio is part of the Business Unit, with responsibility for coordinating Business Development and Post sales activities.

He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager; in this role he was an active member of the team in charge of building up the manufacturing plant, including mechanical installation of all the equipment, completion of commissioning and qualification of the lines, start-up of production.

In 2014, he moved to Business Development to support the strategic growth of the Company, by identifying additional business opportunities with new potential candidates, as well as consolidating already existing partnerships.

Prior to joining BSP Pharmaceuticals, Giorgio worked for 8 years at Bristol Myers-Squibb, where he developed his professional and technical growth, covering different roles with growing responsibilities in Manufacturing and Operation, ended up as Production Manager for Oncology injectable and oral drug product.

Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia.

Ikuo Tsujimoto, M.Sc., is a Research Fellow in the Process Engineering Team at Astellas Pharma Inc. and Head of Cell Manufacturing at Cellafa Bioscience Inc., a joint initiative powered by Astellas and Yaskawa Electric. He earned his master’s degree in biotechnology and has extensive experience in process development and regulatory submissions for Astellas products. He is currently leading efforts to establish robotic cell manufacturing systems named Maholo in a GMP-compliant environment at Cellafa.

Brett Alderson is a veteran leader in the pharmaceutical industry, predominantly working with the manufacturing of sterile injectables. Brett is a determined and thoughtful leader adept at driving business success and leading through transformative change. He is a champion for clients, instilling a client-centric culture, with transparency and helpfulness. He enjoys mentoring and nurturing a diverse workforce with a clear imperative of open and honest communication. Brett has a reputation as an energetic problem solver, acting with integrity and care, and always encourages solutions for a brighter tomorrow by empowering people.

Brett’s career includes more than 25 years at Pfizer (Perth) Pty Ltd., including 5 years as Site Head, where he oversaw a 500-member team and the production of more than 300 Oncology products, plus sterile injectable medicines for local and global markets.

Brett has a bachelor’s degree in applied science in Chemistry from Curtin University.

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into clinic stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications

Abbas Sahili is the CTO of Singzyme, a Singapore based biotech company developing enzymatic, site-selective protein conjugation technologies for the manufacture of antibody-drug conjugates (ADCs) and other bioconjugates. He leads platform development from enzyme engineering through process development, analytics, and scale-up, partnering with industry to enable more homogeneous and manufacturable drug substances. Abbas trained in Structural Biology, Biochemistry and protein engineering and has worked across academia and biotech in Singapore and Europe. His current focus is translating peptide ligase–based conjugation into robust GMP-ready workflows and expanding the platform to new payloads and modalities for oncology and beyond.

Aditya is working as Director, Oncology Medical Lead, MISP Cluster for Pfizer Biopharma. Aditya brings work experience in leading medical strategies/function across multiple therapeutic areas such as Oncology, Immunology, Respiratory, Dermatology, Internal Medicine, etc and has amassed work experience in multiple geographies. Aditya has worked in clinical research in Oncology and has publications in Oncology and Immunology domain. Aditya has led or have been part of pivotal evidence generation and consensus statements. Aditya has championed and contributed to critical compliance and medical affairs processes/systems within pharmaceutical industry. Aditya is a physician with masters in epidemiology and Business Administration.

Dr. Nan Yu is Senior Director and Head of the ADC Medicinal Chemistry Department at Innovent Biologics. As a leading scientist and a key inventor of Innovent's first dual-payload ADC, IBI3020 (DeutTx V1.0), he specializes in the strategic design, synthesis, and optimization of novel linkers and payloads. His research focuses on enhancing therapeutic efficacy and overcoming resistance mechanisms in next-generation ADC development. With extensive hands-on experience and leadership in advancing novel candidates from discovery toward clinical application, Dr. Yu offers a distinct and authoritative perspective in the field.

Dr. Haiqing Hua is a seasoned drug discovery scientist with over 15 years of experience in the research and development (R&D) and manufacturing of innovative pharmaceuticals. He boasts an outstanding track record of leading the discovery of more than 10 innovative drug candidates and advancing them to clinical trials or market approval.

Dr. Hua earned her Bachelor of Science degree from Tsinghua University before pursuing further studies at the University of Zurich, where he obtained his Ph.D. in Molecular Biology. Upon graduation, he has held key positions at Columbia University, Eli Lilly and Company, Hansoh Pharma, and most recently, Duality Biologics. Over the past 15 years, Dr. Hua has focused on the R&D and manufacturing of innovative drugs, overseeing the full lifecycle of biopharmaceuticals from preclinical R&D through clinical translation. As a lead inventor, he has filed more than 20 patents, and his research findings have been published in over 20 prestigious international journals, including Nature, Diabetes, Clinical Cancer Research, and Journal of Clinical Investigation.

Dr. Mu Lin obtained his Ph.D. in Organic Chemistry from Peking University. He has 11 years of biotech industry expertise in the medicinal chemistry of small molecule drug discovery, and 4 years of specialized experience in ADC discovery. He joined Nona Biosciences in 2022, where he is responsible for XDC conjugation and novel linker-drug chemistry.

Ms. Anandayu Nurfachtiyani is a pharmacist graduated from Universitas Indonesia. She has been working for Badan POM, the Indonesia Food and Drug Authority, for more than 15 years as a GMP inspector for API, medicines and biologicals, including vaccines and blood establishment. She had managed and coordinated the GMP Inspection activities as a Lead GMP Inspectors since 2018. During her time in Badan POM, she worked on the development and implementation of the Quality Management Systems for the accession of Badan POM to PIC/S and to become WHO Listed Authority. She has been representing Badan POM in several international meetings and collaboration projects with organization such as PIC/S, WHO, and ASEAN. She joined WHO as a rotational inspector from January to July 2025 and was involved in conducting inspections on vaccine, API and pharmaceutical products manufacturing facilities as part of the WHO Prequalification Program.

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University. As a principal investigator in Development Center for Biotechnology (DCB), he led several drug discovery projects especially on oncology field. These topics include Top1 inhibitor, Nek2/Hec1 inhibitor, antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). After more than 15 years, he left DCB and joined OBI Pharma as the director of Medicinal Chemistry and focusing on developing anti-Trop2 ADC. In 2022, Dr. Chuang co-founded HoneyBear Biosciences, and serve as the CEO.

Medical affairs leader who aspires to improve patient care through new innovations, shaping access and policy in the healthcare ecosystems and talent development. Extensive pre-launch excellence in new molecular entities and cancer companion diagnostic, with regional experience in APAC.

Innovative and driven scientist with 10 years of experience in drug discovery, cancer immunotherapy, cancer biology and infectious disease diagnosis. Specialise in novel biomarker & therapeutic monoclonal antibody discovery (ADCs, bispecifics), assay development, preclinical development.

Takashi Kaminagayoshi serves as Japan Site Head for Biotherapeutics Process Development at Takeda, where he oversees process development for antibody-based biologics, leading programs end-to-end from development through clinical supply. He drives CMC execution for biologics and leads technology transfer across global programs, advancing process development and manufacturing capabilities through process intensification and digital integration. In addition to his corporate leadership, he serves as Vice Chair of the JPMA Bio Community and as Leader of the ISPE Japan Biologics COP, contributing to the advancement of the biologics industry. He holds both a Ph.D. in Life Sciences and an MBA in Management of Technology.